Correction to Registration Link to Access Phio Pharmaceuticals’ Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024 | Press Releases

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDTMarlborough, Massachusetts–(Newsfile Corp. – October 18, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 18, 2024 | Press Releases

Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts–(Newsfile Corp. – October 18, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT’s 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 16, 2024 | Press Releases

PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts–(Newsfile Corp. – October 16, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free...

Phio Announces Data Showcasing INTASYL’s Role in Helping Immune Cells Target and Kill Cancer Cells

Oct 7, 2024 | Press Releases

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts–(Newsfile Corp. – October 7, 2024) – Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...

Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT’s 2024 Advancing Gene + Cell Therapies for Cancer Conference

Oct 1, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – October 1, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more...